The drug TnV6 was originally described as an activator of p53 and developed for use as an anti-cancer agent (Lain et al. 2008); it was only subsequently found to act in a p53-independent manner as an inhibitor of SIRT1/2. This evidence concerns the gene TP53 and cancer.